New Horizon Health Limited (HK:6606) has released an update.
New Horizon Health Limited, a biotech firm focused on cancer screening in China, has reported ongoing business operations despite a suspension in trading of its shares. The company is addressing audit issues and other allegations through an independent investigation, which has made substantive progress but requires additional time to finalize the 2023 Annual Results. Shareholders and potential investors are being updated on the financial impact and measures taken toward resumption of trading.
For further insights into HK:6606 stock, check out TipRanks’ Stock Analysis page.
